Balyasny Asset Management
CTNM

Balyasny Asset Management’s Contineum Therapeutics CTNM Stock Holding History

Balyasny Asset Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25M Sell
1,522,793
-162,842
-10% -$2.13M 0.03% 616
2026
Q1 		$22M Sell
1,685,635
-157,165
-9% -$2.11M 0.03% 648
2025
Q4 		$21.1M Buy
1,842,800
+891,480
+94% +$10.2M 0.03% 685
2025
Q3 		$11.2M Buy
+951,320
New +$7.67M 0.01% 995

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Balyasny Asset Management's CTNM Position: Q2 2026 in Review

Balyasny Asset Management reduced its Contineum Therapeutics (CTNM) stake by 9.7% in Q2 2026, selling an estimated $2.13M and leaving 1,522,793 shares worth $25M. The position accounts for 0.03% of the portfolio, ranked #616.

Balyasny Asset Management first reported a position in CTNM in Q3 2025 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Balyasny Asset Management held 1,522,793 shares of Contineum Therapeutics worth $25M as of Q2 2026.
  • Balyasny Asset Management sold 162,842 Contineum Therapeutics shares in Q2 2026, an estimated $2.13M.
  • Contineum Therapeutics made up 0.03% of Balyasny Asset Management's portfolio in Q2 2026, its #616 holding.
  • Balyasny Asset Management first reported a position in Contineum Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.